Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20198537 | 0.97 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL12135459 | 0.97 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| Ammonia Solution, Strong SCHEMBL28504683 | 0.95 | FDPS (0.47) | FDPSSMPD1GGPS1 | |
| SCHEMBL6151052 | 0.92 | — | — | |
| SCHEMBL5391830 | 0.86 | FDPS (0.52) | FDPSSMPD1GGPS1 | |
| SCHEMBL1271337 | 0.86 | FDPS (0.52) | FDPSSMPD1GGPS1 | |
| SCHEMBL999922 | 0.86 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL18808043 | 0.86 | FDPS (0.32) | FDPSSMPD1 | |
| SCHEMBL7011302 | 0.84 | FDPS (0.46) | FDPSSMPD1GGPS1 | |
| Methacrylic Acid SCHEMBL28659543 | 0.82 | FDPS (0.39) | FDPSSMPD1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102321066-B | Method for producing aryl-aminopropanols | SALTIGO GMBH | 2014-07-23 | — | — | CN | disclosed |
| CN-102321066-B | Method for producing aryl-aminopropanols | SALTIGO GMBH | 2014-07-23 | — | — | CN | disclosed |
| US-7893281-B2 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2011-02-22 | — | — | US | disclosed |
| US-7893281-B2 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2011-02-22 | — | — | US | disclosed |
| US-20090286997-A1 | PROCESS FOR PREPARING ARYLAMINOPROPANOLS | LANXESS DEUTSCHLAND GMBH (DE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286997-A1 | PROCESS FOR PREPARING ARYLAMINOPROPANOLS | LANXESS DEUTSCHLAND GMBH (DE) | 2009-11-19 | — | — | US | disclosed |
| US-7582776-B2 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7582776-B2 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| EP-1346977-B1 | Method for producing aryl-aminopropanols | SALTIGO GMBH (DE) | 2009-07-22 | — | — | EP | disclosed |
| EP-2060559-A1 | Process for the preparation of enantiomerically pure 3-hydroxy-3-arylpropylamines and their optical stereoisomers | Cadila Pharmaceuticals Limited (IN) | 2009-05-20 | — | — | EP | disclosed |
| US-20080262247-A1 | Process for preparing arylaminopropanols | ECKERT MARKUS | 2008-10-23 | — | — | US | disclosed |
| US-7169938-B2 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2007-01-30 | — | — | US | disclosed |
| US-7169938-B2 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20040116709-A1 | Process for producing optically active n-aryl-1-amino-2-propanol derivatives | KANEKA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20030225153-A1 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| US-20030225153-A1 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-1367053-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1346977-A1 | Method for producing aryl-aminopropanols | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225153-A1 | Process for preparing arylaminopropanols | AHR, CYP1A1, CYP1A2 | FDPS 175/4885SMPD1 4053/4885GGPS1 291/4885 |
| US-20090286997-A1 | PROCESS FOR PREPARING ARYLAMINOPROPANOLS | AHR, CYP1A1, CYP1A2 | FDPS 175/4885SMPD1 4053/4885GGPS1 291/4885 |
| US-20080262247-A1 | Process for preparing arylaminopropanols | CYP1A1, CYP1A2, AHR | FDPS 103/4885SMPD1 3781/4885GGPS1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.